Figure 5. Necdin deficiency decreases the repopulating potential of hematopoietic stem and progenitor cells expressing AML1-ETO9a.

(A) Primary transplantation of fetal liver cells expressing AML1-ETO9a. The frequency of donor-derived cells (CD45.2⁺GFP⁺) in the peripheral blood (PB) of recipient mice at 8 weeks following transplantation was determined by flow cytometry analysis (p=0.2, n=5-6). (B) Survival curve of animals transplanted with WT or Necdin null fetal liver cells expressing AML1-ETO9a (P=0.2, n=5-6). (C) and (D) Secondary transplantation assays using 3 × 10⁵ (C) or 3 ×10⁶ (D) bone marrow cells from mice repopulated with WT or Necdin null fetal liver cell expressing AML1-ETO9a. The frequency of donor-derived cells (CD45.2⁺GFP⁺) in peripheral blood was measured by flow cytometry analysis every four weeks for 16 weeks. (^*p<0.05, ^**p<0.01, n=5). (E) The frequency of donor-derived (CD45.2⁺GFP⁺) myeloid cells (CD11b⁺Gr1⁺), B cells (B220⁺), and T cells (CD3⁺) in the bone marrow of secondary recipient mice at 16 weeks following transplantation was determined by flow cytometry analysis. (F) The frequency of donor-derived (CD45.2⁺GFP⁺) Lin⁻Sca1⁻Kit⁺ and Lin⁻Sca1⁺Kit⁺ cells in the bone marrow of secondary recipient mice at 16 weeks following transplantation was determined by flow cytometry analysis.